CFSAN Constituent Update
February 5, 2014
FDA is reopening, for 60 days, the comment period for specific portions of its final guidance for clinical investigators, sponsors, and institutional review boards (IRBs), entitled “Investigational New Drug Applications (INDs) -- Determining Whether Human Research Studies Can Be Conducted Without an IND,” which was announced in the September 10, 2013 Federal Register. The comment period is reopening only for subsections of the final guidance that address the applicability of the IND regulations to clinical research studies involving cosmetics and foods (including dietary supplements). The Agency is taking this action in response to requests that it provide an additional opportunity to submit comments on these portions of the guidance.
- Investigational New Drug Applications (INDs) —Determining Whether Human Research Studies Can Be Conducted Without an IND
- Federal Register Notice for the Reopening of the Comment Period